Early Menopause and Fertility: Is Ovarian Function Ever Possible to Restore?

Being told that your ovarian reserve is very low—or that you may be approaching menopause earlier than expected—can make pregnancy seem impossible.

But early menopause and fertility are more complex than a simple “fertile or infertile” diagnosis.

Ovarian function declines along a continuum. Some women experience diminished ovarian reserve while still menstruating regularly. Others enter perimenopause with increasingly irregular cycles. Women with premature ovarian insufficiency may have long periods without menstruation but still experience intermittent ovarian activity.

This distinction matters because treatment options depend greatly on how much ovarian activity remains.

For women who still hope to conceive with their own eggs, modern fertility assessment—and increasingly regenerative fertility medicine—focuses on identifying and potentially supporting that remaining ovarian function.

Early Menopause, POI and Perimenopause Are Not the Same

These terms are often used interchangeably, but medically they describe different stages.

Premature ovarian insufficiency (POI) refers to loss or significant reduction of ovarian function before age 40.

Early menopause generally refers to menopause occurring between 40 and 44 years of age.

Perimenopause is the transition leading toward menopause. During this period, estrogen production becomes increasingly variable and menstrual cycles may become shorter, longer or irregular.

Menopause is reached after 12 consecutive months without menstruation when there is no other cause.

Postmenopause describes the years after menopause.

These distinctions are especially important for fertility because ovarian activity can differ dramatically between a 37-year-old woman with POI, a 43-year-old in perimenopause and a woman several years into postmenopause.

What Happens to Fertility Before Menopause?

Ovarian aging begins years before the final menstrual period.

Two changes occur simultaneously:

• The number of remaining follicles progressively decreases.
• The proportion of eggs with chromosomal abnormalities increases with age.

This means that a woman may still menstruate and ovulate while already experiencing a substantial reduction in fertility.

Signs of declining ovarian function can include:

• Shorter or increasingly irregular cycles
• Lower AMH
• Reduced Antral Follicle Count
• Higher FSH
• Poor response during IVF stimulation
• Fewer eggs retrieved than expected for age

However, ovarian reserve tests describe primarily the quantity and expected response of the remaining follicular pool. They do not directly determine whether pregnancy is possible.

Can You Still Ovulate with Premature Ovarian Insufficiency?

Yes.

This is one of the most important differences between POI and permanent postmenopausal ovarian inactivity.

Women with non-surgical POI can experience intermittent ovarian function, and spontaneous ovulation and natural conception can occasionally occur. Current international POI guidance specifically recognizes that ovarian activity may recur unpredictably.

This is why the word insufficiency is preferred to the older term “ovarian failure.”

The ovaries may not function consistently, but they are not necessarily completely inactive.

For a woman who wants a pregnancy with her own eggs, detecting this residual activity can be clinically important.

How Is Remaining Ovarian Function Assessed?

Evaluation usually combines several pieces of information rather than relying on one blood test.

These may include:

• Menstrual history
• AMH
• FSH and estradiol
• Antral Follicle Count
• Transvaginal ultrasound
• Previous response to ovarian stimulation
• Evidence of spontaneous follicular development

AMH can be extremely low or even undetectable in POI, while FSH may be elevated. Current ASRM guidance uses menstrual disturbance together with biochemical evidence of ovarian insufficiency for diagnosis.

Importantly, assessment should distinguish very low ovarian reserve from complete absence of ovarian activity.

That distinction can influence whether treatment with the patient’s own eggs is still worth considering.

Early Menopause and Fertility: What Are the Pregnancy Options?

Treatment depends on age, residual follicular activity and reproductive goals.

IVF with your own eggs

If follicles can still be recruited, IVF may remain possible.

The challenge is often obtaining enough mature oocytes, particularly when ovarian response is poor.

Some women may require more than one stimulation cycle to accumulate embryos.

Natural conception

Women with intermittent ovarian activity may occasionally ovulate spontaneously.

Pregnancy therefore remains biologically possible during perimenopause and in some cases of non-surgical POI, although the probability may be low.

Donor eggs

Egg donation provides another route to pregnancy when useful ovarian activity is no longer obtainable.

Because the uterus does not undergo reproductive aging in exactly the same way as the ovaries, many women can carry a pregnancy using donated oocytes after their own ovarian function has substantially declined.

The appropriate strategy depends on whether the objective is maximizing the chance of pregnancy as quickly as possible or first exploring the possibility of conception with the patient’s own eggs.

Can Ovarian Function Be Supported with Regenerative Medicine?

This is one of the most active questions in modern reproductive medicine.

Regenerative approaches aim to influence the ovarian microenvironment rather than simply increasing stimulation medication.

Research and clinical programs have explored techniques including:

• Ovarian PRP
• Enriched PRP
• Mesenchymal stem-cell approaches
• Stem-cell-derived exosomes
• Other regenerative signaling strategies

The biological target may include vascularization, ovarian stromal tissue, granulosa-cell function, inflammation and communication within the remaining follicular environment.

Recent reviews of premature ovarian insufficiency describe encouraging regenerative effects from mesenchymal stem cells and their extracellular vesicles, including effects on follicular survival, angiogenesis, granulosa-cell function and hormonal activity.

The most relevant question is therefore not whether menopause can simply be “reversed,” but whether residual ovarian tissue and follicles remain that may respond to regenerative support.

Ovarian PRP in Women with Early Ovarian Decline

Ovarian PRP is one of the regenerative techniques with the longest clinical history in fertility medicine.

PRP is prepared from the patient’s own blood and delivered directly to ovarian tissue.

For women with early menopause, POI, low ovarian reserve or poor ovarian response, the aim is to support the environment surrounding remaining follicles and potentially improve ovarian activity before natural conception or another IVF attempt.

At Crete Fertility Centre, ovarian PRP has been used since 2016 under the scientific direction of Dr Matthaios Fraidakis. The centre reports experience with more than 4,300 women and specifically includes women with early menopause among those treated.

A published single-centre study led by Dr Fraidakis included 469 women undergoing intraovarian PRP and reported changes in markers of ovarian function following treatment.

This clinical experience is particularly relevant because the patients seeking ovarian rejuvenation often represent very heterogeneous situations—from low ovarian reserve to prolonged menstrual absence.

Enriched PRP, Stem Cells and Exosomes

Regenerative medicine is also developing beyond conventional PRP.

Enriched PRP aims to enhance the regenerative preparation used for ovarian treatment.

Stem-cell approaches focus on cellular and paracrine regenerative activity.

Exosome-based treatments use extracellular vesicles carrying molecular signals involved in cell-to-cell communication.

Research published in 2025–2026 continues to investigate stem-cell and exosome approaches for POI, particularly their potential effects on ovarian fibrosis, oxidative stress, angiogenesis, granulosa-cell survival and follicular development.

For patients, however, the important point is not simply which regenerative technology is newest.

The central issue is whether a biologically meaningful ovarian target remains.

What About Postmenopause?

The situation changes substantially after established natural menopause and particularly after several years of postmenopause.

Residual follicular activity becomes increasingly uncommon.

This is very different from perimenopause or POI, where intermittent ovarian activity may still occur.

Regenerative ovarian research continues to examine endocrine and tissue effects in severe ovarian insufficiency, but expectations must be individualized according to:

• Age
• Duration of amenorrhea
• FSH and AMH
• Ultrasound findings
• Presence of follicles
• Previous ovarian response
• Previous regenerative treatment

A 36-year-old with POI and occasional follicular development should therefore not be approached in the same way as a 52-year-old several years into natural postmenopause.

Why Timing Matters

When fertility is the objective, time remains important.

A regenerative approach should not lead to months or years of repeated treatment without reassessing whether useful ovarian activity is actually occurring.

For women in their late 30s and 40s, both follicle number and oocyte chromosome competence continue to decline with age.

A sensible strategy therefore establishes clear checkpoints.

For example:

Regenerative treatment → ovarian reassessment → evidence of follicular activity → IVF or natural-conception strategy.

If the ovaries respond, the opportunity can be used promptly.

If they do not, other fertility options can be discussed without unnecessary delay.

Early Menopause Is Also a Women’s Health Issue

Early loss of ovarian function affects much more than fertility.

Estrogen deficiency at a young age is associated with consequences for:

• Bone health
• Cardiovascular health
• Sexual health
• Genitourinary health
• Cognitive health
• Emotional well-being

Current POI guidance therefore recommends appropriate hormone therapy until approximately the usual age of menopause for most women with POI, unless contraindicated.

Hormone therapy and fertility treatment have different objectives.

Hormone replacement supports the health consequences of estrogen deficiency.

Fertility treatment addresses the possibility of pregnancy.

Regenerative ovarian treatment explores whether residual ovarian biological function can also be supported.

These approaches can therefore form different parts of the same individualized care plan.

Frequently Asked Questions

Can you get pregnant during perimenopause?

Yes. Ovulation becomes less predictable but does not stop immediately during perimenopause. Natural pregnancy therefore remains possible until menopause occurs.

Is early menopause the same as premature ovarian insufficiency?

No. POI describes ovarian insufficiency before age 40. Early menopause generally refers to menopause from age 40 through 44.

Can periods return after POI?

Intermittent ovarian activity can occur in women with non-surgical POI, and menstruation or ovulation may occasionally resume.

Can regenerative therapy help ovarian function?

PRP, enriched PRP, stem cells and exosome-based approaches target different regenerative pathways within ovarian tissue. Patient selection is especially important because the potential depends heavily on whether residual follicles and ovarian activity remain.

Is ovarian rejuvenation only for women with menopause?

No. Regenerative ovarian approaches may also be considered in selected women with diminished ovarian reserve, low AMH or repeated poor ovarian response before menopause.

Can IVF be performed after ovarian rejuvenation?

Yes. When follicular activity is identified after treatment, ovarian stimulation and IVF may be planned according to the patient’s age, ovarian response and reproductive goals.

Early Menopause and Fertility: Finding the Remaining Opportunity

Early menopause and fertility should not be approached as a simple yes-or-no question.

The reproductive spectrum may progress through:

declining ovarian reserve → perimenopause → early menopause → menopause → postmenopause.

POI can occur much earlier and may still involve intermittent ovarian function.

The key question for women who want to conceive with their own eggs is therefore:

Does useful ovarian activity remain?

When it does, several possibilities may be explored—from natural conception and IVF to regenerative ovarian strategies such as PRP, enriched PRP, stem-cell-based therapy and exosome therapy.

At Chania Fertility Unit, under the scientific direction of Dr Matthaios Fraidakis, regenerative fertility can be integrated with ovarian-reserve assessment and assisted reproduction to determine whether remaining ovarian potential can be meaningfully used.

The objective is neither to treat every woman in the same way nor to define reproductive potential from age or AMH alone.

It is to identify where a woman is within the ovarian-aging process, what biological function remains, and which fertility strategy offers the most meaningful opportunity for her individual situation.